Pierre Fabre Laboratories and Iktos have formed a collaboration
Pierre Fabre Laboratories and Iktos, a specialist in AI and robotics in drug discovery, have formed an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology.
Under the collaboration, Iktos will utilise its AI-driven generative design platform to accelerate the discovery of optimised small-molecule candidates against an undisclosed oncology target. Pierre Fabre Laboratories will contribute its oncology research and preclinical development expertise to guide the selection, evaluation, and advancement of candidate molecules.
Audrey Kauffmann, head of data science and biometry at Pierre Fabre Medical Care R&D, said, “This collaboration with Iktos marks an important milestone in our journey to build an AI-powered R&D engine at Pierre Fabre Laboratories. By integrating Iktos‘ generative AI and automated chemistry technologies into our research platforms, we are taking a step toward realizing our data and AI strategy. This cooperation exemplifies our ambition to leverage cutting-edge innovation to improve the quality and probability of success in drug discovery, while accelerating the delivery of meaningful advances for patients in oncology.”
Olivier Geneste, head of drug discovery at Pierre Fabre Medical Care R&D, said, “We are delighted to start a drug discovery collaboration with Iktos. Thanks to its well-established expertise in generative AI coupled to automated chemistry, we strongly believe that Iktos will help us in accelerating and derisking the discovery of innovative therapeutics targeting a highly valuable oncology target to serve unmet cancer patients’ needs.”
Yann Gaston-Mathé, co-founder and CEO of Iktos, said, “We are delighted to initiate this collaboration with Pierre Fabre Laboratories, a company with a distinguished track record in oncology. This collaboration exemplifies the powerful complementarity between Iktos‘ generative AI and automated chemistry technologies and Pierre Fabre’s deep scientific and clinical development expertise. Together, we intend to create the optimal framework to rapidly and efficiently progress innovative small-molecule candidates in oncology, with the aim of bringing meaningful therapeutic advances to patients worldwide.”